A comprehensive analysis of clinical, quality of life, and cost-effectiveness outcomes of key treatment options for benign prostatic hyperplasia.
Treatment options for men with moderate-to-severe lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH) have variable efficacy, safety, and retreatment profiles, contributing to variations in patient quality of life and healthcare costs. This study examined the long-term cost...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Public Library of Science (PLoS)
2022-01-01
|
| Series: | PLoS ONE |
| Online Access: | https://doi.org/10.1371/journal.pone.0266824 |
| _version_ | 1811344503917772800 |
|---|---|
| author | Bilal Chughtai Sirikan Rojanasarot Kurt Neeser Dmitry Gultyaev Shuai Fu Samir K Bhattacharyya Ahmad M El-Arabi Ben J Cutone Kevin T McVary |
| author_facet | Bilal Chughtai Sirikan Rojanasarot Kurt Neeser Dmitry Gultyaev Shuai Fu Samir K Bhattacharyya Ahmad M El-Arabi Ben J Cutone Kevin T McVary |
| author_sort | Bilal Chughtai |
| collection | DOAJ |
| description | Treatment options for men with moderate-to-severe lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH) have variable efficacy, safety, and retreatment profiles, contributing to variations in patient quality of life and healthcare costs. This study examined the long-term cost-effectiveness of generic combination therapy (CT), prostatic urethral lift (PUL), water vapor thermal therapy (WVTT), photoselective vaporization of the prostate (PVP), and transurethral resection of the prostate (TURP) for the treatment of BPH. A systematic literature review was performed to identify clinical trials of CT, PUL, WVTT, PVP, and TURP that reported change in International Prostate Symptom Score (IPSS) for men with BPH and a prostate volume ≤80 cm3. A random-effects network meta-analysis was used to account for the differences in patient baseline clinical characteristics between trials. An Excel-based Markov model was developed with a cohort of males with a mean age of 63 and an average IPSS of 22 to assess the cost-effectiveness of these treatment options at 1 and 5 years from a US Medicare perspective. Procedural and adverse event (AE)-related costs were based on 2021 Medicare reimbursement rates. Total Medicare costs at 5 years were highest for PUL ($9,580), followed by generic CT ($8,223), TURP ($6,328), PVP ($6,152), and WVTT ($2,655). The total cost of PUL was driven by procedural ($7,258) and retreatment ($1,168) costs. At 5 years, CT and PUL were associated with fewer quality-adjusted life years (QALYs) than WVTT, PVP, and TURP. Compared to WVTT, the incremental cost-effectiveness ratios (ICERs) for both TURP and PVP were above a willingness-to-pay threshold of $50,000/QALY (TURP: $64,409/QALY; PVP: $87,483/QALY). This study provides long-term cost-effectiveness evidence for several common treatment options for men with BPH. WVTT is an effective and economically viable treatment in resource-constrained environments. |
| first_indexed | 2024-04-13T19:49:17Z |
| format | Article |
| id | doaj.art-7f7fd6e063534139b9b1180c23b00d36 |
| institution | Directory Open Access Journal |
| issn | 1932-6203 |
| language | English |
| last_indexed | 2024-04-13T19:49:17Z |
| publishDate | 2022-01-01 |
| publisher | Public Library of Science (PLoS) |
| record_format | Article |
| series | PLoS ONE |
| spelling | doaj.art-7f7fd6e063534139b9b1180c23b00d362022-12-22T02:32:37ZengPublic Library of Science (PLoS)PLoS ONE1932-62032022-01-01174e026682410.1371/journal.pone.0266824A comprehensive analysis of clinical, quality of life, and cost-effectiveness outcomes of key treatment options for benign prostatic hyperplasia.Bilal ChughtaiSirikan RojanasarotKurt NeeserDmitry GultyaevShuai FuSamir K BhattacharyyaAhmad M El-ArabiBen J CutoneKevin T McVaryTreatment options for men with moderate-to-severe lower urinary tract symptoms (LUTS) due to benign prostatic hyperplasia (BPH) have variable efficacy, safety, and retreatment profiles, contributing to variations in patient quality of life and healthcare costs. This study examined the long-term cost-effectiveness of generic combination therapy (CT), prostatic urethral lift (PUL), water vapor thermal therapy (WVTT), photoselective vaporization of the prostate (PVP), and transurethral resection of the prostate (TURP) for the treatment of BPH. A systematic literature review was performed to identify clinical trials of CT, PUL, WVTT, PVP, and TURP that reported change in International Prostate Symptom Score (IPSS) for men with BPH and a prostate volume ≤80 cm3. A random-effects network meta-analysis was used to account for the differences in patient baseline clinical characteristics between trials. An Excel-based Markov model was developed with a cohort of males with a mean age of 63 and an average IPSS of 22 to assess the cost-effectiveness of these treatment options at 1 and 5 years from a US Medicare perspective. Procedural and adverse event (AE)-related costs were based on 2021 Medicare reimbursement rates. Total Medicare costs at 5 years were highest for PUL ($9,580), followed by generic CT ($8,223), TURP ($6,328), PVP ($6,152), and WVTT ($2,655). The total cost of PUL was driven by procedural ($7,258) and retreatment ($1,168) costs. At 5 years, CT and PUL were associated with fewer quality-adjusted life years (QALYs) than WVTT, PVP, and TURP. Compared to WVTT, the incremental cost-effectiveness ratios (ICERs) for both TURP and PVP were above a willingness-to-pay threshold of $50,000/QALY (TURP: $64,409/QALY; PVP: $87,483/QALY). This study provides long-term cost-effectiveness evidence for several common treatment options for men with BPH. WVTT is an effective and economically viable treatment in resource-constrained environments.https://doi.org/10.1371/journal.pone.0266824 |
| spellingShingle | Bilal Chughtai Sirikan Rojanasarot Kurt Neeser Dmitry Gultyaev Shuai Fu Samir K Bhattacharyya Ahmad M El-Arabi Ben J Cutone Kevin T McVary A comprehensive analysis of clinical, quality of life, and cost-effectiveness outcomes of key treatment options for benign prostatic hyperplasia. PLoS ONE |
| title | A comprehensive analysis of clinical, quality of life, and cost-effectiveness outcomes of key treatment options for benign prostatic hyperplasia. |
| title_full | A comprehensive analysis of clinical, quality of life, and cost-effectiveness outcomes of key treatment options for benign prostatic hyperplasia. |
| title_fullStr | A comprehensive analysis of clinical, quality of life, and cost-effectiveness outcomes of key treatment options for benign prostatic hyperplasia. |
| title_full_unstemmed | A comprehensive analysis of clinical, quality of life, and cost-effectiveness outcomes of key treatment options for benign prostatic hyperplasia. |
| title_short | A comprehensive analysis of clinical, quality of life, and cost-effectiveness outcomes of key treatment options for benign prostatic hyperplasia. |
| title_sort | comprehensive analysis of clinical quality of life and cost effectiveness outcomes of key treatment options for benign prostatic hyperplasia |
| url | https://doi.org/10.1371/journal.pone.0266824 |
| work_keys_str_mv | AT bilalchughtai acomprehensiveanalysisofclinicalqualityoflifeandcosteffectivenessoutcomesofkeytreatmentoptionsforbenignprostatichyperplasia AT sirikanrojanasarot acomprehensiveanalysisofclinicalqualityoflifeandcosteffectivenessoutcomesofkeytreatmentoptionsforbenignprostatichyperplasia AT kurtneeser acomprehensiveanalysisofclinicalqualityoflifeandcosteffectivenessoutcomesofkeytreatmentoptionsforbenignprostatichyperplasia AT dmitrygultyaev acomprehensiveanalysisofclinicalqualityoflifeandcosteffectivenessoutcomesofkeytreatmentoptionsforbenignprostatichyperplasia AT shuaifu acomprehensiveanalysisofclinicalqualityoflifeandcosteffectivenessoutcomesofkeytreatmentoptionsforbenignprostatichyperplasia AT samirkbhattacharyya acomprehensiveanalysisofclinicalqualityoflifeandcosteffectivenessoutcomesofkeytreatmentoptionsforbenignprostatichyperplasia AT ahmadmelarabi acomprehensiveanalysisofclinicalqualityoflifeandcosteffectivenessoutcomesofkeytreatmentoptionsforbenignprostatichyperplasia AT benjcutone acomprehensiveanalysisofclinicalqualityoflifeandcosteffectivenessoutcomesofkeytreatmentoptionsforbenignprostatichyperplasia AT kevintmcvary acomprehensiveanalysisofclinicalqualityoflifeandcosteffectivenessoutcomesofkeytreatmentoptionsforbenignprostatichyperplasia AT bilalchughtai comprehensiveanalysisofclinicalqualityoflifeandcosteffectivenessoutcomesofkeytreatmentoptionsforbenignprostatichyperplasia AT sirikanrojanasarot comprehensiveanalysisofclinicalqualityoflifeandcosteffectivenessoutcomesofkeytreatmentoptionsforbenignprostatichyperplasia AT kurtneeser comprehensiveanalysisofclinicalqualityoflifeandcosteffectivenessoutcomesofkeytreatmentoptionsforbenignprostatichyperplasia AT dmitrygultyaev comprehensiveanalysisofclinicalqualityoflifeandcosteffectivenessoutcomesofkeytreatmentoptionsforbenignprostatichyperplasia AT shuaifu comprehensiveanalysisofclinicalqualityoflifeandcosteffectivenessoutcomesofkeytreatmentoptionsforbenignprostatichyperplasia AT samirkbhattacharyya comprehensiveanalysisofclinicalqualityoflifeandcosteffectivenessoutcomesofkeytreatmentoptionsforbenignprostatichyperplasia AT ahmadmelarabi comprehensiveanalysisofclinicalqualityoflifeandcosteffectivenessoutcomesofkeytreatmentoptionsforbenignprostatichyperplasia AT benjcutone comprehensiveanalysisofclinicalqualityoflifeandcosteffectivenessoutcomesofkeytreatmentoptionsforbenignprostatichyperplasia AT kevintmcvary comprehensiveanalysisofclinicalqualityoflifeandcosteffectivenessoutcomesofkeytreatmentoptionsforbenignprostatichyperplasia |